Document:

SECURITY AGREEMENT

            THIS SECURITY AGREEMENT (this "Agreement"),  dated as of November 1,
1999,  is made between  NORTH  AMERICAN  VACCINE,  INC., a Canadian  corporation
("Debtor")  and BAXTER  INTERNATIONAL,  INC., a Delaware  corporation  ("Secured
Party").

         Debtor and Secured Party hereby agree as follows:

         SECTION 1  DEFINITIONS; INTERPRETATION.

         (a) All  capitalized  terms used in this  Agreement  and not  otherwise
defined  herein  shall have the meanings  assigned to them in the  Reimbursement
Agreement.

         (b) As used in this  Agreement,  the  following  terms  shall  have the
following meanings:

         "BANK" means Bank of America, N.A.

         "LOAN  AGREEMENT"  means the loan  agreement  dated  November  1, 1999,
between  Bank and  Debtor,  pursuant  to which Bank has  agreed to make  certain
revolving loans to Debtor.

         "COLLATERAL" has the meaning set forth in Section 2.

         "DOCUMENTS" means the Reimbursement  Agreement and all other documents,
agreements and instruments delivered to Secured Party in connection therewith or
with the Obligations.

         "EVENT OF DEFAULT" has the meaning set forth in Section 8.

         "LIEN" means any mortgage,  deed of trust,  pledge,  security interest,
assignment,  deposit arrangement,  charge or encumbrance, lien, or other type of
preferential arrangement.

         "REIMBURSEMENT  AGREEMENT" means that certain  Reimbursement  Agreement
dated  November  1, 1999 made by Debtor in favor of Secured  Party,  as amended,
modified, renewed, extended or replaced from time to time.

         "OBLIGATIONS" means the indebtedness, liabilities and other obligations
of Debtor to Secured  Party under or in connection  with this  Agreement and the
other  Documents,  including,  without  limitation,  all amounts owing under the
Reimbursement  Agreement and all fees and all other amounts payable by Debtor to
Secured Party  thereunder or in  connection  therewith,  whether now existing or
hereafter  arising,  and whether due or to become due,  absolute or  contingent,
liquidated or unliquidated, determined or undetermined.

<PAGE>

         "PERMITTED LIEN" means (i) any Lien in favor of Secured Party; (ii) any
Lien  that  is  subordinate  to the  Lien  on the  Collateral  created  by  this
Agreement;  (iii) any Lien in favor of Bank of America,  N.A. under that certain
credit agreement dated as of November 1, 1999; (iv) any Liens existing as of the
date hereof and disclosed in writing to Secured Party.

         "PERSON" means an individual, corporation,  partnership, joint venture,
trust,  unincorporated  organization,  governmental agency or authority,  or any
other entity of whatever nature.

         "UCC" means the Uniform  Commercial  Code as the same may, from time to
time,  be in effect in the State of New York;  PROVIDED,  HOWEVER,  in the event
that, by reason of mandatory  provisions  of law, any or all of the  attachment,
perfection or priority of the security interest in any Collateral is governed by
the Uniform  Commercial Code as in effect in a jurisdiction other than the State
of New York, the term "UCC" shall mean the Uniform  Commercial Code as in effect
in such other  jurisdiction  for purposes of the provisions  hereof  relating to
such attachment,  perfection or priority and for purposes of definitions related
to such provisions.

         (c) Where applicable and except as otherwise defined herein, terms used
in this Agreement shall have the meanings assigned to them in the UCC.

         (d) In this  Agreement,  (i) the  meaning  of  defined  terms  shall be
equally  applicable to both the singular and plural forms of the terms  defined;
and (ii) the captions and headings  are for  convenience  of reference  only and
shall not affect the construction of this Agreement.

         SECTION 2  SECURITY INTEREST.

         (a) As security  for the payment and  performance  of the  Obligations,
Debtor hereby pledges, assigns, transfers, hypothecates and sets over to Secured
Party,  and  hereby  grants to  Secured  Party a  security  interest  in, all of
Debtor's  right,  title and  interest in, to and under the  following  property,
wherever  located  and whether now  existing or owned or  hereafter  acquired or
arising (collectively, the "Collateral"):

         (i)   all  accounts,  accounts  receivable, contract  rights, rights to
payment,  chattel paper,  letters of credit,  documents,  securities,  money and
instruments,  and  investment  property,  whether  held  directly  or  through a
securities  intermediary,  and other  obligations  of any kind  owed to  Debtor,
however evidenced;

         (ii)  all deposits and deposit accounts with any bank, savings and loan
association,  credit  union or like  organization,  and all  funds  and  amounts
therein,  and  whether or not held in trust,  or in custody or  safekeeping,  or
otherwise restricted or designated for a particular purpose;

         (iii) all inventory,  including, without limitation, all materials, raw
materials,  parts, components,  work in progress,  finished goods,  merchandise,
supplies,  and all  other  goods  which  are  held  for  sale,  lease  or  other
disposition  or  furnished  under  contracts  of service or consumed in Debtor's

                                       2.
<PAGE>

business, including, without limitation, those held for display or demonstration
or out on lease or consignment;

         (iv)  all equipment,  including,  without  limitation,  all  machinery,
furniture,  furnishings,  fixtures,  trade fixtures,  tools, parts and supplies,
automobiles, trucks, tractors and other vehicles, appliances, computer and other
electronic  data  processing  equipment  and other  office  equipment,  computer
programs and related data processing software, and all additions, substitutions,
replacements,  parts,  accessories,  and  accessions  to and for the  foregoing;
excluding,  however,  the  equipment  collateral  identified  in the  agreements
referred to in Schedule 4(c)(ii) of the Loan Agreement;

         (v)   all general  intangibles and other  personal  property of Debtor,
including, without limitation, (A) all tax and other refunds, rebates or credits
of every  kind and  nature  to  which  Debtor  is now or  hereafter  may  become
entitled;  (B) all  intellectual  property and all rights therein of any type or
description,  including,  without  limitation,  all inventions and  discoveries,
patents and patent  applications,  copyrights  and  applications  for  copyright
(together with the underlying  works of authorship)  whether or not  registered,
together with any renewals and extensions thereof, trademarks, service marks and
trade names, and applications for registration of such trademarks, service marks
and trade names, trade secrets,  trade dress, trade styles,  logos, other source
of  business  identifiers,   mask-works,   mask-work  registrations,   mask-work
applications,  software,  confidential  and  proprietary  information,  customer
lists, other license rights, advertising materials,  operating manuals, methods,
processes,   know-how,   algorithms,   formulae,   databases,   quality  control
procedures, product, service and technical specifications, operating, production
and quality control manuals, sales literature,  drawings,  specifications,  blue
prints,  descriptions,  inventions,  name  plates and  catalogs,  and the entire
goodwill of or  associated  with the  businesses  now or hereafter  conducted by
Debtor connected with and symbolized by any of the aforementioned properties and
assets,  and all  licenses  relating to any of the  foregoing,  all  reissuance,
continuations  and  continuations-in-part  of the  foregoing,  all other  rights
derived from or associated  with the  foregoing,  including the right to sue and
recover  for past  infringement,  and all  income  and  royalties  with  respect
thereto;  (C) all good will,  choses in action  and  causes of  action;  (D) all
interests in limited and general  partnerships and limited liability  companies;
and (E) all indemnity  agreements,  guaranties,  insurance  policies,  insurance
claims,  and other  contractual,  equitable and legal rights of whatever kind or
nature;

         (vi)  all  books,  records  and  other  written,  electronic  or  other
documentation  in whatever form  maintained by or for Debtor in connection  with
the  ownership  of the assets  described in this Section 2 or the conduct of its
business or evidencing or containing information relating to the Collateral; and

         (vii) all products and proceeds,  including insurance proceeds,  of any
and all of the foregoing.

         (b)   Anything herein to the contrary notwithstanding, (i) Debtor shall
remain liable under any contracts,  agreements and other  documents  included in
the  Collateral,  to the extent set forth therein,  to perform all of its duties
and obligations  thereunder to the same extent as if this Agreement had not been

                                       3.
<PAGE>

executed,  (ii) the  exercise  by Secured  Party of any of the rights  hereunder
shall not  release  Debtor  from any of its  duties or  obligations  under  such
contracts,  agreements and other documents included in the Collateral, and (iii)
Secured Party shall not have any  obligation or liability  under any  contracts,
agreements  and other  documents  included in the  Collateral  by reason of this
Agreement,  nor  shall  Secured  Party  be  obligated  to  perform  any  of  the
obligations  or duties of Debtor  thereunder or to take any action to collect or
enforce  any  such  contract,  agreement  or  other  document  included  in  the
Collateral hereunder.

         (c) Notwithstanding  the  foregoing  provisions of  this Section 2, the
grant of a security  interest  as provided  herein  shall not extend to, and the
term "Collateral" shall not include,  (1) that certain U.S. Patent No. 5,425,946
which is covered by a security  interest  in favor of Bankers  Trust  Company as
evidenced by the filing in the U.S.  Patent and Trademark  Office (the "Excluded
Patent Collateral"), and (2) any general intangibles of Debtor (whether owned or
held as licensee or lessee,  or otherwise),  to the extent that (i) such general
intangibles are not assignable or capable of being encumbered as a matter of law
or under the terms of the license,  lease or other agreement  applicable thereto
(but solely to the extent that any such restriction  shall be enforceable  under
applicable law),  without the consent of the licensor or lessor thereof or other
applicable party thereto and (ii) such consent has not been obtained;  PROVIDED,
HOWEVER,  that the foregoing grant of security interest shall extend to, and the
term "Collateral" shall include,  (A) any general intangible which is an account
receivable  or a  proceed  of,  or  otherwise  related  to  the  enforcement  or
collection  of, any  account  receivable,  or goods which are the subject of any
account  receivable,  (B) any and all proceeds of any general  intangibles which
are otherwise  excluded to the extent that the assignment or encumbrance of such
proceeds is not so  restricted,  and (C) upon  obtaining the consent of any such
licensor,  lessor or other  applicable  party's consent with respect to any such
otherwise excluded general intangibles,  such general intangibles as well as any
and all proceeds  thereof that might have  theretofore  have been  excluded from
such grant of a security interest and the term "Collateral."

         (d) This Agreement shall create a continuing  security  interest in the
Collateral  which shall remain in effect until  terminated  in  accordance  with
Section 19 hereof.

         SECTION 3  FINANCING STATEMENTS,  ETC. Debtor shall execute and deliver
to Secured Party  concurrently with the execution of this Agreement,  and at any
time and from time to time thereafter,  all financing  statements,  assignments,
continuation  financing  statements,  termination  statements,  account  control
agreements, and other documents and instruments, in form reasonably satisfactory
to Secured  Party,  and take all other action,  as Secured Party may  reasonably
request, to perfect and continue perfected,  maintain the priority of or provide
notice of the  security  interest  of  Secured  Party in the  Collateral  and to
accomplish the purposes of this Agreement.

         SECTION 4  REPRESENTATIONS  AND  WARRANTIES.   Debtor  represents  and
warrants to Secured Party that:

                                       4.
<PAGE>

         (a) Debtor is a corporation  duly  organized,  validly  existing and in
good standing under the law of the jurisdiction of its incorporation and has all
requisite  power and authority to execute,  deliver and perform its  obligations
under this Agreement.

         (b) The execution, delivery and performance by Debtor of this Agreement
have been duly authorized by all necessary  corporate action of Debtor, and this
Agreement  constitutes  the  legal,  valid and  binding  obligation  of  Debtor,
enforceable  against Debtor in accordance with its terms, except in each case as
such  enforceability  may be limited by bankruptcy,  insolvency  reorganization,
liquidation,  moratorium  or  other  similar  laws of  general  application  and
equitable principles relating to or affecting creditors' rights.

         (c) Except as  otherwise  disclosed  in  writing  by  Debtor to Secured
Party, no authorization,  consent, approval, license, exemption of, or filing or
registration with, any governmental  authority or agency, or approval or consent
of any other Person, is required for the due execution,  delivery or performance
by Debtor of this Agreement.

         (d) Debtor's chief executive  office and principal place of business is
located at the address set forth in SCHEDULE 1; all other locations where Debtor
conducts business or Collateral is kept are set forth in SCHEDULE 1.

         (e)  Except as  otherwise  disclosed  in  writing  by Debtor to Secured
Party,  Debtor is the sole and complete owner of the  Collateral,  free from any
Lien other than Permitted Liens.

         (f) Other than the Excluded  Patent,  Collateral;  all of Debtor's U.S.
and  foreign  patents  and  patent  applications,  copyrights  (whether  or  not
registered),  applications  for copyright,  trademarks,  service marks and trade
names (whether registered or unregistered), and applications for registration of
such trademarks, service marks and trade names, are set forth in SCHEDULE 2.

         SECTION 5 COVENANTS.  So  long   as  any   of  the  Obligations  remain
unsatisfied, Debtor agrees that:

         (a) Debtor  shall appear in and defend any action,  suit or  proceeding
which may affect to a material  extent its title to, or right or interest in, or
Secured Party's right or interest in, the  Collateral,  and shall do and perform
all reasonable acts that may be necessary and appropriate to maintain,  preserve
and protect the Collateral.

         (b) Debtor  shall  comply  in  all  material  respects  with all  laws,
regulations  and  ordinances,  and all  policies  of  insurance,  relating  in a
material  way to the  possession,  operation,  maintenance  and  control  of the
Collateral.

         (c) Debtor shall give prompt  written  notice to Secured  Party (and in
any event not later than 30 days  following any change  described  below in this
subsection)  of: (i) any change in the  location  of  Debtor's  chief  executive
office or principal  place of  business,  (ii) any change in the  locations  set
forth in  Schedule  1;  (iii)  any  change  in its name,  (iv) any  changes  in,
additions  to or other  modifications  of its trade  names and trade  styles set
forth in  Schedule  1 or  Schedule  2, and (v) any  changes in its  identity  or

                                       5.
<PAGE>

structure in any manner which might make any financing statement filed hereunder
incorrect or misleading.

         (d) Debtor shall keep separate, accurate and complete books and records
with respect to the Collateral,  disclosing  Secured Party's  security  interest
hereunder.

         (e) Debtor  shall not  surrender or lose  possession  of (other than to
Secured Party),  sell,  lease,  rent, or otherwise dispose of or transfer any of
the Collateral or any right or interest  therein,  except in the ordinary course
of  business;  PROVIDED  that no such  disposition  or  transfer  of  Collateral
consisting of investment  property or instruments  shall be permitted  while any
Event of Default exists.

         (f) Debtor shall keep the Collateral free of all Liens except Permitted
Liens.

         (g) Debtor shall pay and discharge  all taxes,  fees,  assessments  and
governmental  charges or levies  imposed upon it with respect to the  Collateral
prior to the date on which penalties  attach thereto,  except to the extent such
taxes, fees,  assessments or governmental  charges or levies are being contested
in good faith by appropriate proceedings.

         (h) Debtor shall  maintain and preserve its  corporate  existence,  its
rights to transact  business and all other  rights,  franchises  and  privileges
necessary or desirable in the normal course of its business and  operations  and
the  ownership of the  Collateral,  except in connection  with any  transactions
expressly permitted by the Documents.

         (i) Upon the request of Secured  Party,  Debtor  shall (i)  immediately
deliver to Secured Party, or an agent designated by it,  appropriately  endorsed
or  accompanied  by  appropriate  instruments  of  transfer or  assignment,  all
documents  and  instruments,  all  certificated  securities  with respect to any
investment property,  all letters of credit and all accounts and other rights to
payment at any time evidenced by promissory  notes,  trade  acceptances or other
instruments,  (ii) cause any  securities  intermediaries  to show on their books
that Secured  Party is the  entitlement  holder with  respect to any  investment
property,  and/or obtain  account  control  agreements in favor of Secured Party
from such  securities  intermediaries,  in form and  substance  satisfactory  to
Secured Party, with respect to any investment property,  as requested by Secured
Party,  (iii) mark all  documents and chattel paper with such legends as Secured
Party shall  reasonably  specify,  and (iv) obtain  consents  from any letter of
credit  issuers with respect to the assignment to Secured Party of any letter of
credit proceeds.

         (j) Debtor  shall at any  reasonable  time and from time to time permit
Secured Party or any of its agents or  representatives  to visit the premises of
Debtor  and  inspect  the  Collateral  and to  examine  and make  copies  of and
abstracts from the records and books of account of Debtor.

         (k) Debtor shall: (i) with such frequency as Secured Party may require,
furnish to Secured Party such lists of customers and other information  relating
to the accounts and other  rights to payment as Secured  Party shall  reasonably
request; (ii) give only normal discounts,  allowances and credits as to accounts

                                       6.
<PAGE>

and other rights to payment,  in the ordinary  course of business,  according to
normal trade  practices  utilized by Debtor,  and enforce all accounts and other
rights to payment  strictly in accordance  with their terms,  except that Debtor
may grant any  extension of the time for payment or enter into any  agreement to
make a rebate or  otherwise to reduce the amount owing on or with respect to, or
compromise or settle for less than the full amount thereof, any account or other
right to payment,  in the ordinary  course of business,  according to normal and
prudent  trade  practices  utilized  by Debtor;  and (iii)  upon the  request of
Secured  Party (A) at any time,  notify  all or any  designated  portion  of the
account  debtors and other  obligors on the accounts and other rights to payment
of the security interest  hereunder,  and (B) upon the occurrence and during the
continuance  of an Event of  Default,  notify  the  account  debtors  and  other
obligors on the accounts and other rights to payment or any  designated  portion
thereof that payment  shall be made  directly to Secured  Party or to such other
Person or location as Secured Party shall specify.

         (l) Debtor shall (i) notify Secured Party of any material claim made or
asserted  against  the  Collateral  by  any  Person  and of  any  change  in the
composition  of the Collateral or other event which could  materially  adversely
affect the value of the Collateral or Secured Party's Lien thereon; (ii) furnish
to  Secured  Party  such  statements  and  schedules  further   identifying  and
describing  the  Collateral  and such other  reports  and other  information  in
connection with the Collateral as Secured Party may reasonably  request,  all in
reasonable  detail; and (iii) upon reasonable request of Secured Party make such
demands and requests for  information  and reports as Debtor is entitled to make
in respect of the Collateral.

         (m) If and  when  Debtor  shall  obtain  rights  to  any  new  patents,
trademarks,  service marks,  trade names or copyrights,  or otherwise acquire or
become  entitled  to the benefit  of, or apply for  registration  of, any of the
foregoing,  Debtor (i) shall  promptly  notify  Secured  Party  thereof and (ii)
hereby authorizes Secured Party to modify,  amend, or supplement  SCHEDULE 2 and
from time to time to include  any of the  foregoing  and make all  necessary  or
appropriate filings with respect thereto.

         (n) Debtor shall not enter into any agreement (including any license or
royalty  agreement)  pertaining to any of its patents,  copyrights,  trademarks,
service marks and trade names, except for non-exclusive licenses in the ordinary
course of business.

         (o) Debtor  shall  give  Secured   Party   immediate   notice  of   the
establishment  of any new deposit  account and any new  securities  account with
respect to any investment property.

         SECTION 6  COLLECTION OF ACCOUNTS.  Until Secured  Party  exercises its
rights  hereunder to collect the  accounts  and other rights to payment,  Debtor
shall endeavor in the first instance diligently to collect all amounts due or to
become due on or with respect to the  accounts  and other rights to payment.  At
the request of Secured Party,  upon the occurrence and during the continuance of
any Event of Default,  all remittances received by Debtor shall be held in trust
for Secured Party and, in accordance with Secured Party's instructions, remitted
to  Secured  Party or  deposited  to an  account  of  Secured  Party in the form
received  (with any  necessary  endorsements  or  instruments  of  assignment or
transfer.) At the request of Secured Party, upon and after the occurrence of any
Event of Default,  Secured Party shall be entitled to receive all  distributions

                                       7.
<PAGE>

and  payments  of  any  nature  with  respect  to  any  investment  property  or
instruments, and all such distributions or payments received by the Debtor shall
be held in trust for  Secured  Party and, in  accordance  with  Secured  Party's
instructions,  remitted to Secured Party or deposited to an account with Secured
Party in the form received  (with any necessary  endorsements  or instruments of
assignment  or transfer.)  Following  the  occurrence of an Event of Default any
such distributions and payments with respect to any investment  property held in
any securities account shall be held and retained in such securities account, in
each case as part of the Collateral hereunder. Additionally, Secured Party shall
have the right,  upon the  occurrence  of an Event of Default,  following  prior
written notice to the Debtor,  to vote and to give consents,  ratifications  and
waivers with respect to any investment property and instruments, and to exercise
all rights of conversion, exchange, subscription or any other rights, privileges
or options  pertaining  thereto,  as if Secured  Party were the  absolute  owner
thereof;  PROVIDED  that Secured Party shall have no duty to exercise any of the
foregoing  rights  afforded to it and shall not be  responsible to the Debtor or
any other Person for any failure to do so or delay in doing so.

         SECTION 7  AUTHORIZATION;  SECURED  PARTY  APPOINTED  ATTORNEY-IN-FACT.
Secured Party shall have the right to, in the name of Debtor,  or in the name of
Secured Party or otherwise, upon notice to but without the requirement of assent
by Debtor,  and Debtor hereby constitutes and appoints Secured Party (and any of
Secured Party's  officers,  employees or agents  designated by Secured Party) as
Debtor's true and lawful attorney-in-fact, with full power and authority to: (i)
sign any of the financing  statements and other documents and instruments  which
must be  executed  or filed to  perfect  or  continue  perfected,  maintain  the
priority  of or  provide  notice of Secured  Party's  security  interest  in the
Collateral   (including  any  notices  to  or  agreements  with  any  securities
intermediary);  (ii) assert,  adjust, sue for,  compromise or release any claims
under any  policies  of  insurance;  and (iii)  execute  any and all such  other
documents and instruments,  and do any and all acts and things for and on behalf
of Debtor,  which  Secured Party may deem  reasonably  necessary or advisable to
maintain,  protect, realize upon and preserve the Collateral and Secured Party's
security  interest  therein and to  accomplish  the purposes of this  Agreement.
Secured Party agrees that, except upon and during the continuance of an Event of
Default,  it shall not exercise the power of attorney,  or any rights granted to
Secured  Party,  pursuant  to clauses  (ii) and (iii).  The  foregoing  power of
attorney is coupled with an interest and  irrevocable so long as the Obligations
have not been paid and performed in full. Debtor hereby ratifies,  to the extent
permitted by law, all that Secured Party shall  lawfully and in good faith do or
cause to be done by virtue of and in compliance with this Section 7.

         SECTION 8  EVENTS OF DEFAULT.  Any of the following  events which shall
occur and be continuing shall constitute an "Event of Default":

         (a) Debtor shall fail to pay when due any amount  payable  hereunder or
under the  Reimbursement  Agreement  or any other  Document or in respect of the
Obligations or an "Event of Default" shall occur under the Loan Agreement.

         (b) Any  representation  or warranty by Debtor  under or in  connection
with this Agreement any other Document shall prove to have been incorrect in any
material respect when made or deemed made.

                                       8.
<PAGE>

         (c) Debtor shall fail to perform or observe in any material respect any
other term, covenant or agreement contained in this Agreement, the Reimbursement
Agreement or any other  Document on its part to be performed or observed and any
such failure shall remain  unremedied for a period of 5 days from the occurrence
thereof.

         (d) Any  material  impairment  in the  value of the  Collateral  or the
priority of Secured Party's Lien hereunder.

         (e) Any levy upon, seizure or attachment of any of the Collateral.

         (h) Any Event of Default shall occur under the Bank Credit Agreement.

         SECTION 9  REMEDIES.

         (a) Upon  the  occurrence  and  continuance  of any  Event of  Default,
Secured  Party may  declare any of the  Obligations  to be  immediately  due and
payable and shall have, in addition to all other rights and remedies  granted to
it in this Agreement,  the  Reimbursement  Agreement or any other Document,  all
rights and remedies of a secured party under the UCC and other applicable laws.

         (b) For the purpose of enabling  Secured  Party to exercise  its rights
and  remedies  under  this  Section  9 or  otherwise  in  connection  with  this
Agreement,  Debtor hereby grants to Secured Party an irrevocable,  non-exclusive
and  assignable  license  (exercisable  without  payment  or  royalty  or  other
compensation to Debtor) to use, license or sublicense any intellectual  property
Collateral.

         (c) The  cash  proceeds  actually  received  from  the  sale  or  other
disposition  or collection  of  Collateral,  and any other  amounts  received in
respect of the Collateral the application of which is not otherwise provided for
herein,  shall be applied  FIRST,  to the  payment of the  reasonable  costs and
expenses of Secured Party in exercising or enforcing its rights hereunder and in
collecting or attempting to collect any of the Collateral, and to the payment of
all other amounts  payable to Secured Party  pursuant to Section 13 hereof;  and
SECOND,  to the payment of the  Obligations.  Any surplus  thereof  which exists
after payment and performance in full of the Obligations  shall be promptly paid
over to Debtor or  otherwise  disposed  of in  accordance  with the UCC or other
applicable  law.  Debtor shall remain liable to Secured Party for any deficiency
which exists after any sale or other disposition or collection of Collateral.

         SECTION 10  CERTAIN  WAIVERS.  Debtor  waives,  to the  fullest  extent
permitted by law, (i) any right of  redemption  with respect to the  Collateral,
whether before or after sale hereunder,  and all rights,  if any, of marshalling
of the Collateral or other collateral or security for the Obligations;  (ii) any
right to require Secured Party (A) to proceed against any Person, (B) to exhaust
any other collateral or security for any of the  Obligations,  (C) to pursue any
remedy  in  Secured  Party's  power,  or (D) to make or give  any  presentments,
demands  for  performance,  notices  of  nonperformance,  protests,  notices  of
protests or notices of dishonor in connection  with any of the  Collateral;  and
(iii) all claims,  damages, and demands against Secured Party arising out of the
repossession,  retention, sale or application of the proceeds of any sale of the
Collateral.

                                       9.
<PAGE>

         SECTION 11  NOTICES.  All  notices or  other  communications  hereunder
shall be in writing  (including by facsimile  transmission) and mailed,  sent or
delivered to the respective  parties hereto at or to their respective  addresses
or facsimile  numbers set forth below their names on the signature pages hereof,
or at or to such other address or facsimile number as shall be designated by any
party in a written  notice to the other  parties  hereto.  All such  notices and
other  communications  shall  be  effective  (i)  if  delivered  by  hand,  when
delivered; (ii) if sent by mail, upon the earlier of the date of receipt or five
business days after deposit in the mail, first class [(or air mail, with respect
to communications  to be sent to or from the United States)];  and (iii) if sent
by facsimile transmission, when sent.

         SECTION 12  NO WAIVER; CUMULATIVE  REMEDIES.  No failure on the part of
Secured Party to exercise, and no delay in exercising,  any right, remedy, power
or privilege  hereunder shall operate as a waiver thereof,  nor shall any single
or partial exercise of any such right,  remedy,  power or privilege preclude any
other or further  exercise  thereof or the exercise of any other right,  remedy,
power or privilege.  The rights and remedies under this Agreement are cumulative
and not  exclusive  of any  rights,  remedies,  powers and  privileges  that may
otherwise be available to Secured Party.

         SECTION 13  COSTS AND EXPENSES.

         (a)  Subject to the terms of any other  written fee  agreement  between
Debtor and Secured Party or Guarantor, Debtor agrees to pay on demand:

         (i) [Intentionally omitted];

         (ii) all audit,  consulting,  search,  recording,  filing  and  similar
costs,  fees and expenses  incurred or sustained by Secured  Party in connection
with this Agreement or the Collateral; and

         (iii)  all  costs  and  expenses  of  Secured  Party,  and the fees and
disbursements  of counsel,  in  connection  with the  enforcement  or  attempted
enforcement  of,  and  preservation  of any  rights  or  interests  under,  this
Agreement and the Reimbursement Agreement, including in any out-of-court workout
or  other  refinancing  or  restructuring  or in any  bankruptcy  case,  and the
protection,  sale or  collection  of,  or  other  realization  upon,  any of the
Collateral.

         (b) Any  amounts  payable to  Secured  Party  under this  Section 13 or
otherwise  under this Agreement if not paid upon demand shall bear interest from
the date of such demand until paid in full, at the default rate specified in the
Loan Agreement.

         SECTION 14 BINDING EFFECT.  This Agreement shall be binding upon, inure
to the  benefit  of and be  enforceable  by  Debtor,  Secured  Party  and  their
respective successors and assigns.

         SECTION 15 GOVERNING LAW.  This  Agreement  shall  be  governed by, and
construed  in  accordance  with,  the law of the  State of New  York,  except as
required  by  mandatory  provisions  of law and to the  extent the  validity  or

                                      10.
<PAGE>

perfection of the security interests  hereunder,  or the remedies hereunder,  in
respect of any Collateral  are governed by the law of a jurisdiction  other than
New York.

         SECTION 16  ENTIRE AGREEMENT;  AMENDMENT.  This Agreement  contains the
entire  agreement of the parties with respect to the subject  matter  hereof and
shall not be amended except by the written agreement of the parties.

         SECTION 17  SEVERABILITY.  Whenever possible,  each  provision  of this
Agreement shall be interpreted in such manner as to be effective and valid under
all  applicable  laws  and  regulations.  If,  however,  any  provision  of this
Agreement  shall be prohibited by or invalid under any such law or regulation in
any  jurisdiction,  it shall,  as to such  jurisdiction,  be deemed  modified to
conform to the minimum  requirements  of such law or regulation,  or, if for any
reason it is not deemed so modified, it shall be ineffective and invalid only to
the extent of such  prohibition  or invalidity  without  affecting the remaining
provisions of this Agreement, or the validity or effectiveness of such provision
in any other jurisdiction.

         SECTION 18  COUNTERPARTS.  This Agreement may be executed in any number
of counterparts and by different parties hereto in separate  counterparts,  each
of which when so  executed  shall be deemed to be an  original  and all of which
taken together shall constitute but one and the same agreement.

         SECTION 19  TERMINATION.  Upon payment and  performance  in full of all
Obligations,  this  Agreement  shall  terminate and Secured Party shall promptly
execute  and  deliver  to  Debtor  such  documents  and  instruments  reasonably
requested  by  Debtor  as shall be  necessary  to  evidence  termination  of all
security  interests  given by  Debtor  to  Secured  Party  hereunder;  PROVIDED,
HOWEVER,  that the  obligations  of Debtor under Section 13 hereof shall survive
such termination.

                                       11.
<PAGE>

         IN  WITNESS  WHEREOF,  the  parties  hereto  have  duly  executed  this
Agreement, as of the date first above written.

                                             NORTH AMERICAN VACCINE, INC.

                                             By: /s/ Lawrence J. Hineline
                                                 -------------------------------
                                                 Title: Vice President Finance

                                             10150 Old Columbia Road

                                             Columbia, Maryland  21046

                                             -----------------------------------

                                             Attn: Vice President

                                             Fax:  (410) 309-4077

                                          BAXTER INTERNATIONAL INC.

                                          By:  /s/ Steven J. Meyer
                                               -----------------------
                                               Title:  Corp. Treasurer

<PAGE>

                                   SCHEDULE 1
                            to the Security Agreement

1.  LOCATIONS  OF CHIEF  EXECUTIVE  OFFICE  AND OTHER  LOCATIONS,  INCLUDING  OF
    COLLATERAL

    a. Chief Executive Office and Principal Place of Business:

    North American Vaccine, Inc.
    10150 Old Columbia Road
    Columbia, Maryland 21046

    b. Other locations where Debtor conducts  business or any Collateral is
       kept:

    North American Vaccine, Inc.
    9000 Virginia Manor Road
    Suite 290
    Beltsville, Maryland 20705

    North American Vaccine, Inc.
    12140 Indian Creek Court
    Beltsville, Maryland 20705

    AMVAX, Inc.
    12040 Indian Creek Court
    Beltsville, Maryland  20705

    American Vaccine Corporation
    1105 North Market Street, Suite 940
    Wilmington, Delaware 19801

2.  TRADE NAMES AND TRADE STYLES; OTHER CORPORATE, TRADE OR FICTITIOUS NAMES,
    ETC.

    See Schedule B attached hereto.

                                      S-1.
<PAGE>

                                   SCHEDULE 2
                            to the Security Agreement

1. PATENTS AND PATENT APPLICATIONS.

         See Schedule A attached hereto.

2. COPYRIGHTS (REGISTERED AND UNREGISTERED) AND COPYRIGHT APPLICATIONS.

         None.

3. TRADEMARKS,  SERVICE MARKS AND TRADE NAMES AND  TRADEMARK,  SERVICE MARK AND
   TRADE NAME APPLICATIONS.

         See Schedule B attached hereto.

                                      S-2

<PAGE>

<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------------------------------------------------
                                                                 SCHEDULE A
------------------------------------------------------------------------------------------------------------------------------------
                                                 PATENTS AND PATENT APPLICATIONS OF ASSIGNOR
------------------------------------------------------------------------------------------------------------------------------------
ISSUED U.S. PATENTS
------------------------------------------------------------------------------------------------------------------------------------
<S>                               <C>                <C>                <C>                  <C>                   <C>
Method for the High Level         Blake, et al.      NVX                08/798,760           February 11, 1997     Notice of
Expression, Purification and                         (co-exclusive      (Notice of Allowance                       Allowance issued
Refolding of the Outer Membrane                      license with PMC)  issued Jan. 1999)                          January 1999
Group B Porin Proteins                                                                                             (fee paid April
                                                                                                                   1999)
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level         Blake, et al.      NVX & Rockefeller  5,439,808            August 8, 1995        Patent
Expression, Purification and                         University
Refolding of the Outer Membrane                      (co-exclusive
Group B Porin Proteins from                          license with PMC)
Neisseria Meningitidis
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level         Blake, et al.      NVX                5,747,287            May 5, 1998           Patent
Expression, Purification and                         (co-exclusive
Refolding of the Outer Membrane                      license with PMC)
Group B Porin Proteins from
Neisseria Meningitidis
------------------------------------------------------------------------------------------------------------------------------------
Group A Streptococcal             Blake et al.       NVX & Rockefeller  5,866,135            February 2, 1999      Patent
Polysaccharide Immunogenic                           University
Compositions and Methods
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level         Blake, et al.      NVX                5,879,686            March 9, 1999         Patent
Expression, Purification and                         (co-exclusive
Refolding of the Outer Membrane                      license with PMC)
Group B Porin Proteins from
Neisseria Meningitidis
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------------------------------------------------
U.S. PATENT APPLICATIONS
------------------------------------------------------------------------------------------------------------------------------------
<S>                                      <C>                     <C>           <C>                <C>                  <C>
Method for the High Level                Tai, et al.             NVX           08/096,181         July 23, 1993        Application
Expression, Purification and
Refolding of the Outer Membrane
Protein P2 from Haemophilus Type b
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level                Tai, et al.             NVX           08/449,358          May 24, 1995        Application
Expression, Purification and
Refolding of the Outer Membrane
Protein P2 from Haemophilus Type b
------------------------------------------------------------------------------------------------------------------------------------
Antigenic Group B Streptococcus         Michon, et al.           NVX           08/481,883          June 7, 1995        Application
Type II and Type III
Polysaccharide Fragments Having a
2,5-Anhydro-D-Mannose Terminal
Structure and Conjugate Vaccine
Thereof
------------------------------------------------------------------------------------------------------------------------------------
Direct Methods for Molar-Mass          Michon, D'Ambra           NVX           08/753,242       November 22, 1996      Application
Determination of Fragments of
Haemophilus Type b Capsular
Polysaccharides and Vaccine
Preparation
------------------------------------------------------------------------------------------------------------------------------------
Cloning of Non-IgA FC Binding             Tai, Blake             NVX           08/923,992       September 5, 1997      Application
Forms of the Group B Streptococcal
Beta Antigens
------------------------------------------------------------------------------------------------------------------------------------
Antigenic Group B Streptococcus         Michon, et al.           NVX           09/025,225       February 18, 1998      Application
Type II and Type III
Polysaccharide Fragments Having a
2,5-Anhydro-D-Mannose Terminal
Structure and Conjugate Vaccine
Thereof
------------------------------------------------------------------------------------------------------------------------------------

<PAGE>

------------------------------------------------------------------------------------------------------------------------------------
Immunogenic Conjugates Comprising       Blake, et al.            NVX           09/118/180         July 17, 1998        Application
A Group B Meningococcal Porin and
an H. Influenzae Polysaccharide
------------------------------------------------------------------------------------------------------------------------------------
Modified Immunogenic Pneumolysin       Minetti, et al.           NVX           09/120,044         July 21, 1998        Application
Compositions as Vaccines
------------------------------------------------------------------------------------------------------------------------------------
Group A Streptococcal                    Blake et al.           NVX &          09/207,188        December 8, 1998      Application
Polysaccharide Immunogenic                                   Rockefeller
Compositions and Methods                                     University
------------------------------------------------------------------------------------------------------------------------------------
Procedures for the Extraction and       Michon, Blake            NVX           09/221,620       December 23, 1998      Application
Isolation of Bacterial Capsular
Polysaccharides for Use as
Vaccines or Linked to Proteins as
Conjugate Vaccines
------------------------------------------------------------------------------------------------------------------------------------
Gram Positive Bacterial Antigens       Long-Rowe, Blake          NVX           09/399,220       September 17, 1999     Application
and Methods of Purification of the
Streptococcal C-Beta Protein
------------------------------------------------------------------------------------------------------------------------------------
Immunogenic Polysaccharide-Protein      Michon et al.            NVX           09/376,911        August 18, 1999       Application
Conjugate Useful as a Vaccine
Produced Via Conjugation Through a
CZ-3 N-Acyl Portion F A
Polysaccharide
------------------------------------------------------------------------------------------------------------------------------------

</TABLE>
                                       A-1

<PAGE>

<TABLE>
<CAPTION>

---------------------------------------------------------------------------------------------------------------------------
                                                                 SCHEDULE B
---------------------------------------------------------------------------------------------------------------------------
                                                         U.S. TRADEMARKS OF ASSIGNOR
---------------------------------------------------------------------------------------------------------------------------
MARK                               STATUS              APPL NO./     APPL./REGIS. DATE        OWNER OF RECORD
                                                       REGIS. NO.
---------------------------------------------------------------------------------------------------------------------------
     REGISTERED U.S. TRADEMARKS
---------------------------------------------------------------------------------------------------------------------------
<S>                                <C>                 <C>           <C>                      <C>
Globe Design                       Registered          1,932,111     October 31, 1995         North American Vaccine, Inc.
---------------------------------------------------------------------------------------------------------------------------
AMVAX                              Registered          1,967,632     April 16, 1996           North American Vaccine, Inc.
---------------------------------------------------------------------------------------------------------------------------
TRINAVACEL                         Registered          2,101,121     September 30, 1997       American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
TRIVAX                             Registered          2,118,360     December 2, 1997         American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
NAVA                               Registered          2,267,812     August 3, 1999           American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
     PENDING U.S. TRADEMARK APPLICATIONS
---------------------------------------------------------------------------------------------------------------------------
THE IMPORTANCE OF OUR WORK         Pending             75/190,826    October 29, 1996         American Vaccine Corporation
GROWS BIGGER EVERY DAY
---------------------------------------------------------------------------------------------------------------------------
NEISVAC-C                          Pending             Not Avail.    August 26, 1999          American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
NEISIVA                            Pending             Not Avail.    August 26, 1999          American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
MENCIVA                            Pending             Not Avail.    August 26, 1999          American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-2PATENT AND TRADEMARK ASSIGNMENT AND SECURITY AGREEMENT

            THIS PATENT AND TRADEMARK  ASSIGNMENT AND SECURITY  AGREEMENT  (this
"Agreement"),  dated as of  November 1, 1999,  is made  between  NORTH  AMERICAN
VACCINE,  INC., a Canadian corporation  ("Assignor"),  and BANK OF AMERICA, N.A.
("Assignee").

            Assignor and Assignee are parties to a Security  Agreement  dated as
of  November 1, 1999 (as  amended,  modified,  renewed or extended  from time to
time, the "Security Agreement"),  which Security Agreement provides, among other
things,  for the  assignment  by Assignor to Assignee,  and grant by Assignor to
Assignee of a security  interest in, certain of Assignor's  property and assets,
including,  without  limitation,  its  patents  and  patent  applications,   its
trademarks, service marks and trade names, and its applications for registration
of such  trademarks,  service  marks  and  trade  names.  Pursuant  to the  Loan
Agreement  Assignor has agreed to execute and deliver this Agreement to Assignee
for filing with the United States  Patent and Trademark  Office (the "PTO") (and
any other relevant  recording systems in any domestic or foreign  jurisdiction),
and as further  evidence of and to effectuate  such assignment of and grant of a
security interest in such patents and patent applications,  trademarks,  service
marks and trade names,  and  applications  for  registration of such trademarks,
service  marks and trade  names,  and the other  general  intangibles  described
herein. Accordingly, Assignor and Assignee hereby agree as follows:

            SECTION 1  DEFINITIONS; INTERPRETATION.

            (a) All  capitalized  terms used in this Agreement and not otherwise
defined  herein  shall  have  the  meanings  assigned  to them  in the  Security
Agreement.

            (b) In this  Agreement,  (i) the  meaning of defined  terms shall be
equally  applicable to both the singular and plural forms of the terms  defined;
and (ii) the captions and headings  are for  convenience  of reference  only and
shall not affect the construction of this Agreement.

            SECTION 2  ASSIGNMENT AND GRANT OF SECURITY INTEREST.

            (a)     As  security  for  the  payment  and   performance   of  the
Obligations  (as defined in the Security  Agreement),  Assignor  hereby assigns,
transfers  and  conveys  and  grants a  security  interest  in and  mortgage  to
Assignee, for security purposes, all of Assignor's right, title and interest in,
to and under the following property,  whether now existing or owned or hereafter
acquired,  developed  or  arising  (collectively,   the  "Intellectual  Property
Collateral"):

            (i)     all  patents and patent  applications,  domestic or foreign,
all licenses  relating to any of the foregoing and all income and royalties with
respect to any licenses (including,  without limitation, such patents and patent
applications  as  described  in SCHEDULE A hereto),  all rights to sue for past,
present  or future  infringement  thereof,  all  rights  arising  therefrom  and
pertaining  thereto  and  all  reissues,  divisions,  continuations,   renewals,
extensions and continuations-in-part thereof;

<PAGE>

            (ii)    all  state  (including  common  law),  federal  and  foreign
trademarks,  service marks and trade names, and applications for registration of
such trademarks,  service marks and trade names, all licenses relating to any of
the  foregoing  and all  income  and  royalties  with  respect  to any  licenses
(including,  without limitation, such marks, names and applications as described
in  SCHEDULE  B  hereto),   whether  registered  or  unregistered  and  wherever
registered,  all  rights to sue for past,  present  or  future  infringement  or
unconsented use thereof, all rights arising therefrom and pertaining thereto and
all reissues, extensions and renewals thereof;

            (iii)   the entire goodwill of or associated with the businesses now
or hereafter  conducted by Assignor  connected with and symbolized by any of the
aforementioned properties and assets;

            (iv)    all  general  intangibles  (as  defined  in the UCC) and all
intangible intellectual or other similar property of the Assignor of any kind or
nature,  associated with or arising out of any of the aforementioned  properties
and assets and not otherwise described above; and

            (v)     all products and proceeds of any and all of the foregoing.

            (a)     This Agreement shall create a continuing  security  interest
in the  Intellectual  Property  Collateral  which shall  remain in effect  until
terminated in accordance with Section 17 hereof.

            (b)     Notwithstanding the foregoing  provisions of this Section 2,
the grant of a security interest as provided herein shall not extend to, and the
term "Intellectual Property Collateral" shall not include, (1) that certain U.S.
Patent No. 5,425,946 which is covered by a security interest in favor of Bankers
Trust Company as evidenced by the filing in the U.S. Patent and Trademark Office
(the "Excluded Patent  Collateral"),  and (2) any general  intangibles of Debtor
(whether owned or held as licensee or lessee, or otherwise),  to the extent that
(i) such general  intangibles are not assignable or capable of being  encumbered
as a matter of law or under the terms of the license,  lease or other  agreement
applicable  thereto (but solely to the extent that any such restriction shall be
enforceable under applicable law), without the consent of the licensor or lessor
thereof or other  applicable  party  thereto and (ii) such  consent has not been
obtained; PROVIDED, HOWEVER, that the foregoing grant of security interest shall
extend to, and the term "Intellectual  Property  Collateral" shall include,  (A)
any  general  intangible  which is an  account  receivable  or a proceed  of, or
otherwise  related to the enforcement or collection of, any account  receivable,
or goods  which  are the  subject  of any  account  receivable,  (B) any and all
proceeds of any general  intangibles which are otherwise  excluded to the extent
that the assignment or  encumbrance  of such proceeds is not so restricted,  and
(C) upon obtaining the consent of any such licensor,  lessor or other applicable
party's consent with respect to any such otherwise excluded general intangibles,
such general intangibles as well as any and all proceeds thereof that might have
theretofore  have been excluded  from such grant of a security  interest and the
term "Intellectual Property Collateral."

            SECTION  3  FURTHER   ASSURANCES;   APPOINTMENT   OF   ASSIGNEE   AS
    ATTORNEY-IN-FACT.  Assignor at its expense  shall  execute and  deliver,  or
    cause to be executed and  delivered,  to Assignee any and all  documents and

                                       2
<PAGE>

    instruments,  in form and substance  satisfactory to Assignee,  and take any
    and all action,  which Assignee may reasonably request from time to time, to
    perfect and continue  perfected,  maintain the priority of or provide notice
    of Assignee's security interest in the Intellectual  Property Collateral and
    to accomplish the purposes of this Agreement.  Assignee shall have the right
    to, in the name of the  Assignor,  or in the name of Assignee or  otherwise,
    without  notice  to or  assent  by the  Assignor,  and the  Assignor  hereby
    irrevocably  constitutes  and  appoints  Assignee  (and  any  of  Assignee's
    officers or employees or agents  designated  by Assignee) as the  Assignor's
    true and lawful attorney-in-fact with full power and authority,  (i) to sign
    the name of the Assignor on all or any of such documents or instruments  and
    perform all other acts that Assignee  deems  necessary or advisable in order
    to perfect or continue perfected, maintain the priority or enforceability of
    or provide  notice of  Assignee's  security  interest  in, the  Intellectual
    Property  Collateral,  and (ii) to execute any and all other  documents  and
    instruments, and to perform any and all acts and things for and on behalf of
    the Assignor,  which  Assignee may deem  necessary or advisable to maintain,
    preserve and protect the Intellectual  Property Collateral and to accomplish
    the purposes of this Agreement,  including (A) to defend,  settle, adjust or
    (after the occurrence of any Event of Default) institute any action, suit or
    proceeding with respect to the Intellectual Property Collateral,  and, after
    the  occurrence of any Event of Default,  (B) to assert or retain any rights
    under any license agreement for any of the Intellectual Property Collateral,
    including  without  limitation  any  rights of the  Assignor  arising  under
    Section 365(n) of the  Bankruptcy  Code, and (C) after the occurrence of any
    Event of Default, to execute any and all applications, documents, papers and
    instruments for Assignee to use the  Intellectual  Property  Collateral,  to
    grant or issue any exclusive or  non-exclusive  license or sub-license  with
    respect to any Intellectual  Property Collateral,  and to assign,  convey or
    otherwise  transfer  title  in  or  dispose  of  the  Intellectual  Property
    Collateral;  PROVIDED,  HOWEVER,  that in no event shall  Assignee  have the
    unilateral  power,  prior to the occurrence and  continuation of an Event of
    Default,  to  assign  any of the  Intellectual  Property  Collateral  to any
    Person,  including  itself,  without the  Assignor's  written  consent.  The
    foregoing shall in no way limit Assignee's rights and remedies upon or after
    the  occurrence  of an Event of Default.  The power of attorney set forth in
    this Section 3, being coupled with an interest,  is  irrevocable  so long as
    this Agreement shall not have terminated in accordance with Section 17.

            SECTION 4  FUTURE RIGHTS.  Except as otherwise  expressly  agreed to
in writing by Assignee,  if and when the Assignor shall obtain rights to any new
patentable  inventions or any new trademarks,  or become entitled to the benefit
of any of the  foregoing,  or obtain  rights or  benefits  with  respect  to any
reissue, division,  continuation,  renewal, extension or continuation-in-part of
any patents or trademarks,  or any improvement of any patent,  the provisions of
Section 2 shall  automatically  apply  thereto  and the  Assignor  shall give to
Assignee prompt notice thereof. Assignor shall do all things deemed necessary or
advisable  by  Assignee  to  ensure  the  validity,  perfection,   priority  and
enforceability  of the security  interests  of Assignee in such future  acquired
Intellectual Property Collateral. Assignor hereby authorizes Assignee to modify,
amend,  or supplement the Schedules  hereto and to reexecute this Agreement from
time to time on  Assignor's  behalf and as its  attorney-in-fact  to include any
such future Intellectual

                                        3
<PAGE>

    Property Collateral and to cause such reexecuted Agreement or such modified,
    amended or supplemented Schedules to be filed with PTO.

            SECTION 5  ASSIGNEE'S   DUTIES.    Notwithstanding   any   provision
contained in this Agreement,  Assignee shall have no duty to exercise any of the
rights,  privileges or powers afforded to it and shall not be responsible to the
Assignor  or any other  Person  for any  failure  to do so or delay in doing so.
Except for the accounting for moneys actually received by Assignee  hereunder or
in connection herewith,  Assignee shall have no duty or liability to exercise or
preserve  any  rights,  privileges  or  powers  pertaining  to the  Intellectual
Property Collateral.

            SECTION 6  REPRESENTATIONS AND WARRANTIES.  Assignor  represents and
    warrants to Assignee that:

            (a) A true  and  correct  list of all of the  existing  Intellectual
Property  Collateral  consisting of U.S. patents and patent  applications and/or
registrations  owned  by the  Assignor,  in whole or in  part,  and  pledged  as
collateral hereunder, is set forth in SCHEDULE A.

            (b) A true  and  correct  list of all of the  existing  Intellectual
Property  Collateral  consisting  of U.S.  trademarks,  trademark  registrations
and/or  applications owned by the Assignor,  in whole or in part, and pledged as
collateral hereunder is set forth in SCHEDULE B.

            (c) All  patents,  trademarks,  service  marks  and  trade  names of
Assignor are subsisting and have not been adjudged  invalid or  unenforceable in
whole or in part.

            (d) All  maintenance  fees  required  to be paid on  account  of any
patents or  trademarks of Assignor  have been timely paid for  maintaining  such
patents and trademarks in force, and, to the best of Assignor's knowledge,  each
of the patents and trademarks  constituting  part of the  Intellectual  Property
Collateral is valid and enforceable.

            (e) To the  best of  Assignor's  knowledge  after  due  inquiry,  no
material  infringement  or  unauthorized  use  presently  is  being  made of any
Intellectual Property Collateral by any Person.

            (f) Except as  otherwise  disclosed  in writing by Debtor to Secured
Party,  Assignor is the sole and exclusive  owner of the  Intellectual  Property
Collateral  and  the  past,   present  and  contemplated   future  use  of  such
Intellectual  Property  Collateral  by Assignor  has not,  does not and will not
infringe or violate any right,  privilege  or license  agreement  of or with any
other Person.

            SECTION 7  COVENANTS.

            (a)  Assignor  will  appear  in  and  defend  any  action,  suit  or
proceeding  which may  affect to a material  extent its title to, or  Assignee's
rights or interest in, the Intellectual Property Collateral.

                                        4
<PAGE>

            (b)  Assignor  will not allow or suffer  any  Intellectual  Property
Collateral to become abandoned,  nor any registration  thereof to be terminated,
forfeited, expired or dedicated to the public.

            (c) Assignor will diligently  prosecute all applications for patents
and   trademarks,   and  file   and   prosecute   any  and  all   continuations,
continuations-in-part, applications for reissue, applications for certificate of
correction and like matters as shall be reasonable and appropriate in accordance
with  prudent  business  practice,  and  promptly  pay any and all  maintenance,
license,  registration and other fees, taxes and expenses incurred in connection
with any Intellectual Property Collateral.

            SECTION 8  ASSIGNEE'S RIGHTS AND REMEDIES.

            (a) Assignee  shall  have all rights and  remedies  available  to it
under the  Security  Agreement,  the other  Documents  and  applicable  law with
respect to the security interests in any of the Intellectual Property Collateral
or any other collateral.  Assignor agrees that such rights and remedies include,
but are not  limited  to, the right of  Assignee  as a secured  party to sell or
otherwise  dispose of its collateral after default pursuant to the UCC. Assignor
agrees that Assignee shall at all times have such royalty free licenses,  to the
extent permitted by law and to the extent of Assignor's rights therein,  for any
Intellectual  Property  Collateral that shall be reasonably  necessary to permit
the  exercise  of any of  Assignee's  rights  or  remedies  upon  or  after  the
occurrence  of an Event of  Default  and  shall  additionally  have the right to
license and/or sublicense any Intellectual Property Collateral upon or after the
occurrence of an Event of Default,  whether general,  special or otherwise,  and
whether  on an  exclusive  or a  nonexclusive  basis,  any of  the  Intellectual
Property  Collateral,  throughout  the world  for such  term or  terms,  on such
conditions,  and in such  manner,  as  Assignee  in its  sole  discretion  shall
determine.  In addition to and without  limiting any of the foregoing,  upon the
occurrence  and during the  continuance  of an Event of Default,  Assignee shall
have the right but shall in no way be obligated  to bring suit,  or to take such
other  action as  Assignee  deems  necessary  or  advisable,  in the name of the
Assignor or  Assignee,  to enforce or protect any of the  Intellectual  Property
Collateral,  in which event the Assignor shall,  at the request of Assignee,  do
any and all lawful acts and execute any and all  documents  required by Assignee
in aid of such enforcement. To the extent that Assignee shall elect not to bring
suit to enforce such Intellectual  Property  Collateral,  Assignor agrees to use
all  reasonable  measures and its  diligent  efforts,  whether by action,  suit,
proceeding  or  otherwise,  to prevent  the  infringement,  misappropriation  or
violations  thereof by others and for that purpose agrees diligently to maintain
any action,  suit or  proceeding  against any Person  necessary  to prevent such
infringement, misappropriation or violation.

            (b) The  cash  proceeds  actually  received  from  the sale or other
disposition or collection of  Intellectual  Property  Collateral,  and any other
amounts  received  in  respect  of  the  Intellectual  Property  Collateral  the
application of which is not otherwise  provided for herein,  shall be applied as
provided in the Security Agreement.

            SECTION 9 NOTICES.  All  notices or other  communications  hereunder
shall be in writing (including by facsimile  transmission) shall be mailed, sent
or delivered in accordance with the Security Agreement at or to their respective

                                       5
<PAGE>

addresses  or  facsimile  numbers set forth  below their names on the  signature
pages  hereof,  or at or to such other  address or facsimile  number as shall be
designated  by any party in a written  notice to the other parties  hereto.  All
such  notices and other  communications  shall be  effective  as provided in the
Security Agreement.

            SECTION 10  NO WAIVER;  CUMULATIVE REMEDIES.  No failure on the part
of Assignee to exercise, and no delay in exercising, any right, remedy, power or
privilege  hereunder shall operate as a waiver thereof,  nor shall any single or
partial  exercise of any such right,  remedy,  power or  privilege  preclude any
other or further  exercise  thereof or the exercise of any other right,  remedy,
power or privilege.  The rights and remedies under this Agreement are cumulative
and not  exclusive  of any  rights,  remedies,  powers and  privileges  that may
otherwise be available to Assignee.

            SECTION 11  COSTS AND EXPENSES; INDEMNITY.

            (a) Assignor  agrees to  pay on demand  all  costs and  expenses  of
Assignee,  including without  limitation all attorneys' fees, in connection with
the enforcement or attempted  enforcement of, and  preservation of any rights or
interests under, this Agreement,  and the assignment,  sale or other disposal of
any of the Intellectual Property Collateral.

            (b) Assignor  hereby  agrees to indemnify  Assignee,  any  affiliate
thereof, and their respective directors,  officers,  employees,  agents, counsel
and other advisors (each an "Indemnified Person") against, and hold each of them
harmless from, any and all liabilities,  obligations,  losses, claims,  damages,
penalties,  actions,  judgments,  suits, costs, expenses or disbursements of any
kind or nature whatsoever,  including, without limitation, reasonable attorneys'
fees and attorneys'  fees incurred  pursuant to 11 U.S.C.,  which may be imposed
on, incurred by, or asserted against any Indemnified Person, in any way relating
to  or  arising  out  of  this  Agreement,  including  in  connection  with  any
infringement or alleged  infringement with respect to any Intellectual  Property
Collateral,  or any action  taken or omitted  to be taken by it  hereunder  (the
"Indemnified  Liabilities");  PROVIDED that Assignor  shall not be liable to any
Indemnified Person for any portion of such Indemnified Liabilities to the extent
they are found by a final decision of a court of competent  jurisdiction to have
resulted from such Indemnified  Person's gross negligence or willful misconduct.
If and to the extent that the foregoing  indemnification  is for any reason held
unenforceable,  Assignor agrees to make the maximum  contribution to the payment
and  satisfaction  of each of the Indemnified  Liabilities  which is permissible
under applicable law.

            (c) Any  amounts  payable  to  Assignee  under  this  Section  11 or
otherwise  under this Agreement if not paid upon demand shall bear interest from
the date of such demand until paid in full,  at the default rate of interest set
forth in the Loan Agreement.

            SECTION 12 BINDING  EFFECT.  This  Agreement  shall be binding upon,
inure to the  benefit of and be  enforceable  by  Assignor,  Assignee  and their
respective successors and assigns.

                                       6
<PAGE>

            SECTION 13  GOVERNING LAW. This Agreement  shall be governed by, and
    construed in accordance  with,  the law of the State of New York,  except to
    the extent that the validity or  perfection of the  assignment  and security
    interests  hereunder in respect of any Intellectual  Property Collateral are
    governed by federal law and except to the extent  that  Assignee  shall have
    greater  rights or remedies  under federal law, in which case such choice of
    New York law shall not be deemed to  deprive  Assignee  of such  rights  and
    remedies as may be available under federal law.

            SECTION 14  AMENDMENT. This Agreement shall not be amended except by
    the written agreement of the parties.

            SECTION 15 SEVERABILITY.  Whenever possible,  each provision of this
    Agreement  shall be  interpreted in such manner as to be effective and valid
    under all applicable laws and  regulations.  If,  however,  any provision of
    this  Agreement  shall be  prohibited  by or  invalid  under any such law or
    regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed
    modified to conform to the minimum  requirements  of such law or regulation,
    or, if for any reason it is not deemed so modified,  it shall be ineffective
    and invalid only to the extent of such  prohibition  or  invalidity  without
    affecting the remaining  provisions  of this  Agreement,  or the validity or
    effectiveness of such provision in any other jurisdiction.

            SECTION 16  COUNTERPARTS.  This  Agreement  may be  executed  in any
    number  of  counterparts  and  by  different   parties  hereto  in  separate
    counterparts,  each of  which  when so  executed  shall be  deemed  to be an
    original and all of which taken  together  shall  constitute but one and the
    same agreement.

            SECTION 17  TERMINATION. Upon payment and performance in full of all
    Obligations,  this  Agreement  shall  terminate and Assignee  shall promptly
    execute and deliver to Assignor such  documents and  instruments  reasonably
    requested by Assignor as shall be necessary to evidence  termination  of all
    security  interests  given by  Assignor  to  Assignee  hereunder,  including
    cancellation  of this  Agreement by written notice from Assignee to the PTO;
    PROVIDED,  HOWEVER, that the obligations of Assignor under Section 11 hereof
    shall survive such termination.

            SECTION 18  SECURITY  AGREEMENT.   Assignor  acknowledges  that  the
    rights and remedies of Assignee  with  respect to the security  interests in
    the Intellectual Property Collateral granted hereby are more fully set forth
    in the Security Agreement and all such rights and remedies are cumulative.

            SECTION 19  NO INCONSISTENT REQUIREMENTS. Assignor acknowledges that
    this  Agreement and the Security  Agreement may contain  covenants and other
    terms and provisions variously stated regarding the same or similar matters,
    and the Assignor  agrees that all such  covenants,  terms and provisions are
    cumulative and all shall be performed and satisfied in accordance with their
    respective terms.

                                        7
<PAGE>

            IN WITNESS  WHEREOF,  the  parties  hereto have duly  executed  this
Agreement, as of the date first above written.

                                     NORTH AMERICAN VACCINE, INC.

                                     By /s/ Lawrence J. Hineline
                                        -----------------------------
                                        Title: Vice-President Finance

                                     10150 Old Columbia Road
                                     Columbia, Maryland  21046
                                     Attn: Vice-President
                                     Fax: (410) 309-4077

                                     BANK OF AMERICA, N.A.

                                     By /s/ Lawrence J. Gordon
                                        -----------------------------
                                        Title: Vice-President

                                     Bank of America Center
                                     700 Louisiana Street,
                                     TX4-213-08-10
                                     Houston, Texas 77002-2700
                                     Attn: Lawrence J. Gordon
                                     Fax: (713) 247-6719

                                        8
<PAGE>

STATE OF Texas   )
                 ) ss
COUNTY OF Harris )

                On November 2, 1999,  before me, Beth L. Erwin,  Notary  Public,
personally appeared Larry J. Gordon,  personally known to me (or proved to me on
the basis of  satisfactory  evidence) to be the person(s)  whose name(s)  is/are
subscribed to the within  instrument  and  acknowledged  to me that  he/she/they
executed  the  same  in  his/her/their  authorized  capacity(ies),  and  that by
his/her/their  signature(s) on the instrument the person(s),  or the entity upon
behalf of which the person(s) acted, executed the instrument.

            WITNESS my hand and official seal.

                                        /s/ Beth L. Erwin
                                        -----------------
                                        Signature

[SEAL]

                                        9
<PAGE>

STATE OF CALIFORNIA         )
                            )  ss
COUNTY OF _________________ )

            On ___________ , before me, _____________, Notary Public, personally
appeared ___________________________, personally known to me (or proved to me on
the basis of  satisfactory  evidence) to be the person(s)  whose name(s)  is/are
subscribed to the within  instrument  and  acknowledged  to me that  he/she/they
executed  the  same  in  his/her/their  authorized  capacity(ies),  and  that by
his/her/their  signature(s) on the instrument the person(s),  or the entity upon
behalf of which the person(s) acted, executed the instrument.

            WITNESS my hand and official seal.

                                        ____________________________________
                                        Signature

[SEAL]

                                       10
<PAGE>

<TABLE>
<CAPTION>

                                                                 SCHEDULE A
------------------------------------------------------------------------------------------------------------------------------------
                                                 PATENTS AND PATENT APPLICATIONS OF ASSIGNOR
------------------------------------------------------------------------------------------------------------------------------------
ISSUED U.S. PATENTS
------------------------------------------------------------------------------------------------------------------------------------
<S>                               <C>                <C>                <C>                  <C>                   <C>
Method for the High Level         Blake, et al.      NVX                08/798,760           February 11, 1997     Notice of
Expression, Purification and                         (co-exclusive      (Notice of Allowance                       Allowance issued
Refolding of the Outer Membrane                      license with PMC)  issued Jan. 1999)                          January 1999
Group B Porin Proteins                                                                                             (fee paid April
                                                                                                                   1999)
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level         Blake, et al.      NVX & Rockefeller  5,439,808            August 8, 1995        Patent
Expression, Purification and                         University
Refolding of the Outer Membrane                      (co-exclusive
Group B Porin Proteins from                          license with PMC)
Neisseria Meningitidis
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level         Blake, et al.      NVX                5,747,287            May 5, 1998           Patent
Expression, Purification and                         (co-exclusive
Refolding of the Outer Membrane                      license with PMC)
Group B Porin Proteins from
Neisseria Meningitidis
------------------------------------------------------------------------------------------------------------------------------------
Group A Streptococcal             Blake et al.       NVX & Rockefeller  5,866,135            February 2, 1999      Patent
Polysaccharide Immunogenic                           University
Compositions and Methods
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level         Blake, et al.      NVX                5,879,686            March 9, 1999         Patent
Expression, Purification and                         (co-exclusive
Refolding of the Outer Membrane                      license with PMC)
Group B Porin Proteins from
Neisseria Meningitidis
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
U.S. PATENT APPLICATIONS
------------------------------------------------------------------------------------------------------------------------------------
<S>                                      <C>                     <C>           <C>                <C>                  <C>
Method for the High Level                Tai, et al.             NVX           08/096,181         July 23, 1993        Application
Expression, Purification and
Refolding of the Outer Membrane
Protein P2 from Haemophilus Type b
------------------------------------------------------------------------------------------------------------------------------------
Method for the High Level                Tai, et al.             NVX           08/449,358          May 24, 1995        Application
Expression, Purification and
Refolding of the Outer Membrane
Protein P2 from Haemophilus Type b
------------------------------------------------------------------------------------------------------------------------------------
Antigenic Group B Streptococcus         Michon, et al.           NVX           08/481,883          June 7, 1995        Application
Type II and Type III
Polysaccharide Fragments Having a
2,5-Anhydro-D-Mannose Terminal
Structure and Conjugate Vaccine
Thereof
------------------------------------------------------------------------------------------------------------------------------------
Direct Methods for Molar-Mass          Michon, D'Ambra           NVX           08/753,242       November 22, 1996      Application
Determination of Fragments of
Haemophilus Type b Capsular
Polysaccharides and Vaccine
Preparation
------------------------------------------------------------------------------------------------------------------------------------
Cloning of Non-IgA FC Binding             Tai, Blake             NVX           08/923,992       September 5, 1997      Application
Forms of the Group B Streptococcal
Beta Antigens
------------------------------------------------------------------------------------------------------------------------------------
Antigenic Group B Streptococcus         Michon, et al.           NVX           09/025,225       February 18, 1998      Application
Type II and Type III
Polysaccharide Fragments Having a
2,5-Anhydro-D-Mannose Terminal
Structure and Conjugate Vaccine
Thereof
------------------------------------------------------------------------------------------------------------------------------------

<PAGE>

------------------------------------------------------------------------------------------------------------------------------------
Immunogenic Conjugates Comprising       Blake, et al.            NVX           09/118/180         July 17, 1998        Application
A Group B Meningococcal Porin and
an H. Influenzae Polysaccharide
------------------------------------------------------------------------------------------------------------------------------------
Modified Immunogenic Pneumolysin       Minetti, et al.           NVX           09/120,044         July 21, 1998        Application
Compositions as Vaccines
------------------------------------------------------------------------------------------------------------------------------------
Group A Streptococcal                    Blake et al.           NVX &          09/207,188        December 8, 1998      Application
Polysaccharide Immunogenic                                   Rockefeller
Compositions and Methods                                     University
------------------------------------------------------------------------------------------------------------------------------------
Procedures for the Extraction and       Michon, Blake            NVX           09/221,620       December 23, 1998      Application
Isolation of Bacterial Capsular
Polysaccharides for Use as
Vaccines or Linked to Proteins as
Conjugate Vaccines
------------------------------------------------------------------------------------------------------------------------------------
Gram Positive Bacterial Antigens       Long-Rowe, Blake          NVX           09/399,220       September 17, 1999     Application
and Methods of Purification of the
Streptococcal C-Beta Protein
------------------------------------------------------------------------------------------------------------------------------------
Immunogenic Polysaccharide-Protein      Michon et al.            NVX           09/376,911        August 18, 1999       Application
Conjugate Useful as a Vaccine
Produced Via Conjugation Through a
CZ-3 N-Acyl Portion F A
Polysaccharide
------------------------------------------------------------------------------------------------------------------------------------

</TABLE>

                                      A-1
<PAGE>

<TABLE>
<CAPTION>

---------------------------------------------------------------------------------------------------------------------------
                                                                 SCHEDULE B
---------------------------------------------------------------------------------------------------------------------------
                                                         U.S. TRADEMARKS OF ASSIGNOR
---------------------------------------------------------------------------------------------------------------------------
MARK                               STATUS              APPL NO./     APPL./REGIS. DATE        OWNER OF RECORD
                                                       REGIS. NO.
---------------------------------------------------------------------------------------------------------------------------
     REGISTERED U.S. TRADEMARKS
---------------------------------------------------------------------------------------------------------------------------
<S>                                <C>                 <C>           <C>                      <C>
Globe Design                       Registered          1,932,111     October 31, 1995         North American Vaccine, Inc.
---------------------------------------------------------------------------------------------------------------------------
AMVAX                              Registered          1,967,632     April 16, 1996           North American Vaccine, Inc.
---------------------------------------------------------------------------------------------------------------------------
TRINAVACEL                         Registered          2,101,121     September 30, 1997       American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
TRIVAX                             Registered          2,118,360     December 2, 1997         American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
NAVA                               Registered          2,267,812     August 3, 1999           American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
     PENDING U.S. TRADEMARK APPLICATIONS
---------------------------------------------------------------------------------------------------------------------------
THE IMPORTANCE OF OUR WORK         Pending             75/190,826    October 29, 1996         American Vaccine Corporation
GROWS BIGGER EVERY DAY
---------------------------------------------------------------------------------------------------------------------------
NEISVAC-C                          Pending             Not Avail.    August 26, 1999          American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
NEISIVA                            Pending             Not Avail.    August 26, 1999          American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
MENCIVA                            Pending             Not Avail.    August 26, 1999          American Vaccine Corporation
---------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]